{"links":{"html":"https://www.erudio.com/reports/proud-pv-nct01949805","json":"https://www.erudio.com/reports/proud-pv-nct01949805.json","markdown":"https://www.erudio.com/reports/proud-pv-nct01949805.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"proud-pv-01949805"}},"request":"https://www.erudio.com/contact?report=proud-pv-01949805"},"offer":{"cited_commentary_sources":30,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a licence key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, to join with NPI-keyed systems such as a CRM. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":26,"optional":true,"price_per_verified_person_usd":15,"price_usd":390,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One licence key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"proud-pv-nct01949805"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the licence key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=proud-pv-01949805","people":"Tom and Audun, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/proud-pv-nct01949805","renewal":"Subscriptions are prepaid and do not renew automatically.","terms":"https://www.erudio.com/terms"},"size":"standard","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-08T19:15:10.421595Z","notify_subscribers":false,"status":"corrected","summary":"Duplicate cards for the same person were combined"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":17,"no_commentary_found":0},"aspects":[{"claim_count":11,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Disease response rate"},{"claim_count":18,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":9,"title":"Secondary endpoints"},{"claim_count":21,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":12,"title":"Population and setting"},{"claim_count":22,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":35,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":11,"title":"Safety and tolerability"},{"claim_count":22,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":8,"title":"Design and conduct"},{"claim_count":35,"coverage":"discussed","id":"A1","source_count":12,"title":"Clinical meaning and actionability of JAK2 molecular response"},{"claim_count":50,"coverage":"discussed","id":"A2","source_count":8,"title":"Adding cytoreduction in conventionally low-risk PV"},{"claim_count":30,"coverage":"discussed","id":"A3","source_count":9,"title":"Early response versus sustained benefit and extension interpretation"},{"claim_count":39,"coverage":"discussed","id":"A4","source_count":8,"title":"Interferon safety, controlled comorbidity and rechallenge"},{"claim_count":46,"coverage":"discussed","id":"A5","source_count":9,"title":"Titration speed, individualization and response–toxicity balance"},{"claim_count":59,"coverage":"discussed","id":"A6","source_count":11,"title":"Molecular monitoring, assay sensitivity and treatment-free periods"},{"claim_count":70,"coverage":"discussed","id":"A7","source_count":14,"title":"Hydroxyurea versus interferon: preferences and constraints"},{"claim_count":70,"coverage":"discussed","id":"A8","source_count":12,"title":"Diagnosis, progression risk and count targets informing selection"},{"claim_count":46,"coverage":"discussed","id":"A9","source_count":6,"title":"Ruxolitinib as an alternative and its upfront evidence question"},{"claim_count":29,"coverage":"discussed","id":"A10","source_count":5,"title":"Rusfertide adjunctive or bridge use and iron-handling uncertainty"},{"claim_count":65,"coverage":"discussed","id":"A11","source_count":14,"title":"Counseling, access, patient support and future treatment questions"}],"counts":{"cited_sources":32,"claims_by_expression_type":{"comparison":112,"experience":93,"interpretation":114,"opinion":133,"primary_context":16,"question":85,"restatement":104,"uncertainty":69,"unspecified":23},"claims_by_kind":{"attributed_opinion":2,"counterview":1,"interpretation":49,"limitation":26,"source_observation":671},"evidence_units":403,"findings":11,"people_cited":33,"people_identity_verified":26,"people_total":44,"screened_sources":33,"verified_claims":749},"depth":"rich","depth_rule":"thin if verified claims <30, findings <5, or cited sources <10; rich if verified claims >=100, findings >=8, and cited sources >=30; otherwise standard","findings_index":[{"id":"F1","title":"Molecular response is gaining clinical meaning, but its role in changing treatment remains contested"},{"id":"F2","title":"Earlier cytoreduction in low-risk PV attracts support, but deferral remains an active-management position"},{"id":"F3","title":"The favorable reading is time-dependent and must remain beside the early endpoint and extension qualifications"},{"id":"F4","title":"Improved tolerability does not remove psychiatric, autoimmune or organ-specific selection and stopping concerns"},{"id":"F5","title":"Faster titration is an unanswered benefit–toxicity trade-off, not a proven route to better clinical outcomes"},{"id":"F6","title":"Treatment-free periods are selective experiences, not a routine promise or evidence of cure"},{"id":"F7","title":"Hydroxyurea remains a credible choice; interferon preference is shaped by time horizon, patient priorities and specific constraints"},{"id":"F8","title":"Risk assessment and diagnostic work-up are treated as conditions for therapy, not as a single age or laboratory cutoff"},{"id":"F9","title":"Ruxolitinib is a symptom- and failure-driven alternative, with upfront positioning and long-exposure safety still questioned"},{"id":"F10","title":"Rusfertide is discussed chiefly as an adjunct or bridge, not as a substitute for anticlonal treatment"},{"id":"F11","title":"Patient expectations, access and research support are part of the treatment conversation"}],"medical_affairs_question":"What evidence would make molecular response actionable after blood counts normalize?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Molecular relevance is emerging; treatment actionability is not agreed"},{"id":"section-2","level":2,"title":"Early treatment and active deferral reflect different evidence thresholds"},{"id":"section-3","level":2,"title":"Delayed benefit does not rewrite the early endpoint or extension"},{"id":"section-4","level":2,"title":"Improved tolerability still requires selection and stopping boundaries"},{"id":"section-5","level":2,"title":"Faster count control must be tested against toxicity and persistence"},{"id":"section-6","level":2,"title":"Treatment-free experience depends on selection, testing and cautious expectations"},{"id":"section-7","level":2,"title":"Hydroxyurea's practical value persists beside conditional interferon preference"},{"id":"section-8","level":2,"title":"Diagnostic certainty and distinct risks condition treatment choices"},{"id":"section-9","level":2,"title":"Symptom-driven ruxolitinib use does not settle its upfront role"},{"id":"section-10","level":2,"title":"Rusfertide's place depends on the aim: adjunct, bridge or solo treatment?"},{"id":"section-11","level":2,"title":"Patient expectations extend beyond response measures"},{"id":"section-12","level":3,"title":"Prevention, support and access shape treatment choices"},{"id":"section-13","level":3,"title":"Future interest remains bounded by questions and evidence type"},{"id":"section-14","level":3,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3"},"identity":{"accepted_at":"2026-10-08T19:15:10.421595Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-08T19:43:17Z","record_hash":"998310e4e19ba6fe878eadfec6e71eb1d5beb36f2184348559ed58058ce18587","release_hash":"7aa5a3fbfde5fc27a135d21399ccb79d14d11072ca035eef11595dc112da7630","report_id":"erudio-nct01949805","run_id":"149b99c4-1865-415f-98cb-c5bfcec79555","schema_version":"5.0","slug":"proud-pv-01949805","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"PROUD-PV raises a central clinician question: does ropeginterferon offer meaningful long-term benefit compared with hydroxyurea for people with polycythemia vera who need blood-count control? Clinicians discuss molecular response and its clinical relevance, early versus extended follow-up, comparator treatment and extension design, and selection of patients for cytoreduction. Other topics include dose escalation, psychiatric and autoimmune safety, monitoring and treatment-free periods, diagnostic work-up and risk assessment, alternative treatments, and the implications for patient counseling, access and support.","meta_description":"33 HCP sources screened · 749 verified claims from 32 sources · 11 findings. Updated 2026-10-08.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-e66ba5612003d8e6f7e8-a37f4eb0"],"id":"F1","paraphrase":"An X thread asked whether molecular response during ropeginterferon treatment, including a fall in JAK2 allele burden, translates into a change in the course of PV.","source_channel":"x_thread","source_date":"2023-12-10","title":"Molecular response is gaining clinical meaning, but its role in changing treatment remains contested"},{"cited_claim_ids":["claim-099dea8810d5f48ea5f7"],"id":"F3","paraphrase":"A podcast speaker asked whether an abstract concerned the original PROUD-PV study, its CONTINUATION-PV extension or a particular component of longer-term follow-up.","source_channel":"podcast","source_date":"2024-09-13","title":"The favorable reading is time-dependent and must remain beside the early endpoint and extension qualifications"}]},"publication":{"approved_at":"2026-10-08T19:43:17Z","approved_by":"Audun Utengen","corrections":[{"affected_ids":[],"date":"2026-10-08T20:30:00Z","summary":"Duplicate cards for the same person were combined"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"1.0","scope_and_limits":{"commentary_scope":{"basis":"Reviewed retained sources only; not all HCPs or all public discussion.","empty_source_ids":[],"has_known_gaps":true,"held_out_finds":22,"retrieval_gaps":["commentary:coverage_scope:keyword matches to trial identifier and registry aliases; single-letter acronym variants require planned context in the same indexed chunk; unnamed references or other transcription variants may be absent","commentary:indexed_source_unreadable:podcast:episode_id:aa5c88:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:0wUNZNSAZrs:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:9O4VFBhZmpo:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:ElVsbiyxlCo:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:M-0Gu6hRRXg:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:OoIXNEizxsU:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:TUzSDQISwKk:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:UyKhws7pMFI:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:kGTmRdMhbBc:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:nCtwsgugHo0:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:srL1qvzTLcw:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:w3qcUW9KffA:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:xNS5PHs26kQ:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:scribe_unavailable:mcp:podcast:637de2: diarized re-transcription failed; quotes use the discovery transcript.","commentary:scribe_unavailable:mcp:youtube:qkuwwPaCgS0: diarized re-transcription failed; quotes use the discovery transcript.","commentary:held_out:mcp:youtube:LRoD4qGHFMs@28534:30270: a claim attaches the general “icing on the cake” characterization particularly to younger patients. The passage instead makes that characterization generally and separately emphasizes watching BAF in younger patients, as faithfully distinguished in a claim.","commentary:held_out:mcp:youtube:j8ozPM7FknI@12441:14680: a claim drops the history qualification from the recited autoimmune contraindication. The source says “History or presence of active serious or untreated autoimmune disease,” not only currently active disease.","commentary:held_out:mcp:podcast:920b4c@34841:36993: Harrison’s explicit critique that the PROUD-PV population was skewed and highly selected, limiting an unqualified well-tolerated-treatment characterization, is absent from the verified claims and their quotations. This directly qualifies the selected tolerability interpretations; it is not merely a separate MF update.","commentary:held_out:mcp:youtube:VgNrKOKrml4@15151:16558: Mead’s own Mithridate commentary is absent: he links the upfront question to ruxolitinib’s second-line success and highlights a direct physician-choice interferon versus ruxolitinib comparison. a claim retains a different speaker’s account, not this distinct view.","commentary:held_out:mcp:youtube:trPoPvKOOmw@2118:4421: Abu-Zeinah’s Low-PV interpretation is absent from the inventory: he regards the evidence as supporting superiority over phlebotomy plus aspirin for a hematologic-response-without-progression composite, explains that progression also included symptom progression, and emphasizes symptom benefit. Other speakers’ Low-PV accounts do not preserve his view.","commentary:held_out:mcp:youtube:trPoPvKOOmw@4423:6708: The continuation of Abu-Zeinah’s Low-PV account supplies a distinct safety interpretation missing from all claims: few grade 3 events, predominantly grade 1–2 events, and his view that neutropenia and liver-enzyme abnormalities were generally not clinically significant, with dose reduction available for liver abnormalities.","commentary:held_out:mcp:youtube:vqeVMOgxmBs@0:2140,mcp:youtube:vqeVMOgxmBs@2142:2598: Kiladjian’s Low-PV add-on account is missing: fixed low-dose ropeg was added to phlebotomy and aspirin, maintained hematocrit below 45%, and was associated in his report with eight progression cases in control versus none with ropeg and allele-burden reduction after two years. a claim–a claim and a claim do not retain these findings.","commentary:held_out:mcp:podcast:920b4c@41853:42043: Andersen’s statement that he could not treat with ropeginterferon because he lacked access is absent. It qualifies the treatment debate’s practical options without establishing a current or PV-specific access restriction.","commentary:held_out:mcp:youtube:j8ozPM7FknI@12441:14680: The selected product-source tolerability account omits additional consequential precautions: untreated or serious autoimmune endocrine disorders, discontinuation for unmanageable endocrine disorders, avoidance in severe or unstable cardiovascular disease or recent stroke/MI, and the recited CBC-monitoring schedule.","commentary:held_out:mcp:youtube:j8ozPM7FknI@12441:14680,mcp:youtube:j8ozPM7FknI@14682:16971: The same source’s organ-specific interruption, discontinuation and monitoring boundaries are absent from the inventory. These include possible pancreatic/colonic/pulmonary toxicity, new or worsening eye disorders, hepatic decompensation, renal impairment and marked triglyceride elevation. They materially qualify the selected favorable long-term manageability interpretation.","commentary:held_out:mcp:youtube:j8ozPM7FknI@14682:16971: The product-source embryo-fetal warning and pregnancy, contraception and breastfeeding precautions are absent from all verified claims and quotations. The report selects favorable pregnancy commentary in a claim, a claim and a claim without this supplied formulation-specific countercontext beside that interpretation.","commentary:held_out:mcp:youtube:j8ozPM7FknI@16973:17663: The source’s concomitant-drug disclosure is missing, including avoidance with myelosuppressive agents and specified CNS-active drugs. This is consequential context for the selected temporary hydroxyurea-overlap practice in a claim and broader statements about manageable treatment.","commentary:held_out:mcp:podcast:13964f@2856:6112,mcp:podcast:13964f@6114:6825,mcp:podcast:13964f@7509:8629: Hussein’s clinically connected diagnostic strategy is absent: reviewing count trends and medications before assessment, the falling-MCV/rising-hemoglobin-or-hematocrit pattern and other count abnormalities that raise MPN suspicion, and symptom, thrombosis-history and examination findings used to assess possible PV.","commentary:held_out:mcp:podcast:13964f@9517:12440: Hussein’s initial-investigation and selective-deferral view is missing: a convincing secondary explanation with reassuring findings can lead him to discharge without a PV investigation, whereas doubt prompts JAK2 testing; he describes simultaneous variant testing and EPO as supportive but often equivocal.","commentary:held_out:mcp:podcast:13964f@12442:13616: Hussein’s ultrasound rationale is absent: objective assessment of a difficult-to-feel spleen, liver and kidney assessment, and selective venous assessment with abdominal symptoms, including rare personally detected renal tumors and portal-vein thromboses. This is distinct diagnostic and risk-assessment context for the retained treatment discussion."],"source_count":33,"unreadable_unit_ids":[]},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.","For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","22 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.","13 further source limits are recorded in the machine-readable scope of this record.","Coverage is limited to the reviewed material. Some relevant recordings could not be accessed, and discussion using unnamed trial references or unfamiliar name variants may be absent.","Several sources contain the same conversation in different formats. Their repetition is not independent clinical corroboration, and source counts do not represent independent HCP counts.","Study outcomes, guideline descriptions, approval statements and dosing practices are generally reported by speakers. They remain attributed accounts rather than independently established trial results or prescribing guidance.","Some passages have incomplete sentences, uncertain measures or unclear clinical direction. The report does not supply a missing direction, threshold or referent.","Some speakers are identifiable only by a first name or remain unnamed. John, Toyosi and Tony are retained as established in their respective passages; a fuller identity is not inferred. Elissa Baldwin is retained as a host whose clinical role is unresolved in the supplied professional context.","Comments span different events and publication dates. The EHA22 debate was published in March 2023; later favorable posts or discussions do not establish a change of mind or disagreement across settings.","The supplied primary ancillary analysis was small and preliminary, and its clinical-outcome caveat belongs to that analysis’s period. It neither proves clinical benefit from molecular reduction nor negates later speaker-reported associations."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":11,"publication":2,"registry":0,"regulatory":0,"x_thread":6,"x_video":0,"youtube":13},"by_evidence_role":{"commentary":30,"context":2},"count":32,"evidence_window":{"end":"2026-09-14","start":"2017-01-13"},"retrieval_snapshot":"2026-10-08T03:16:03.864230Z","timeline":[{"count":1,"week":"2017-W02"},{"count":1,"week":"2020-W22"},{"count":1,"week":"2023-W09"},{"count":1,"week":"2023-W16"},{"count":1,"week":"2023-W34"},{"count":1,"week":"2023-W45"},{"count":1,"week":"2023-W48"},{"count":2,"week":"2023-W49"},{"count":1,"week":"2024-W20"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2024-W24"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W27"},{"count":1,"week":"2024-W28"},{"count":2,"week":"2024-W37"},{"count":1,"week":"2024-W38"},{"count":1,"week":"2025-W15"},{"count":1,"week":"2025-W20"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W36"},{"count":2,"week":"2026-W38"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT01949805:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT01949805:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:30287855","quote_policy":"short_quote_link_out"},{"id":"pubmed:42169665","quote_policy":"short_quote_link_out"},{"id":"openfda:e76fd60e-7644-48c5-9857-3608a045000b:20260527","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:13964f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:2a8db4","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6210ad","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:637de2","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8890d6","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:920b4c","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:996c64","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:acc0e7","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ae47fb","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:bb3bfb","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:fd4a23","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1695468502222557244:4a06b899-d551-4e31-b4d7-74aab84c85de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1733577987793051825:13045ece-7eb8-4cb9-9791-b085f34abb46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1733913771306111409:6bddc820-12ac-4a2d-9b07-b07505a362a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1801615067001065702:0e4a304a-cce3-4911-976b-cbbe3826b7cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1808484163604877518:1ece06e2-de2d-4ab7-b74f-e346018a28d3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1922764209890185581:2fa04bfb-5346-4baf-aac3-a72ba07ae3ae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1933864936784187641:d4cd28d1-9c01-4327-a2af-6d4d7baccb16","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1970463795043803495:cf0d5c4e-d8bd-4adb-8c93-edeac8d30c05","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2086471069985042673:d4fe0065-f054-46cb-b4cb-ec71a9a1f55d","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:07rs6ulA5p0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4bZ44Y7Fkl4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:F5XZOaR83Lo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:LRoD4qGHFMs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:VgNrKOKrml4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:X5r-rj8Kl7Y","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:hCviV-bdtwU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:j8ozPM7FknI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:qkuwwPaCgS0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:sBlNuxUrqxg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:trPoPvKOOmw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:vqeVMOgxmBs","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:yQV3Q1_Nmw4","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":11,"publication":0,"registry":0,"regulatory":0,"x_thread":9,"x_video":0,"youtube":13},"by_evidence_role":{"commentary":33},"count":33,"evidence_window":{"end":"2026-09-14","start":"2017-01-13"},"retrieval_snapshot":"2026-10-08T03:16:03.864230Z","timeline":[{"count":1,"week":"2017-W02"},{"count":1,"week":"2020-W22"},{"count":1,"week":"2023-W09"},{"count":1,"week":"2023-W16"},{"count":1,"week":"2023-W34"},{"count":1,"week":"2023-W45"},{"count":1,"week":"2023-W48"},{"count":2,"week":"2023-W49"},{"count":1,"week":"2024-W20"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2024-W24"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W27"},{"count":1,"week":"2024-W28"},{"count":2,"week":"2024-W37"},{"count":1,"week":"2024-W38"},{"count":1,"week":"2025-W15"},{"count":1,"week":"2025-W20"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W39"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W32"},{"count":1,"week":"2026-W36"},{"count":2,"week":"2026-W38"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Besremi"],"label":"ropeginterferon alfa-2b","slug":"ropeginterferon-alfa-2b"},{"brand_names":["Hydrea"],"label":"hydroxyurea","slug":"hydroxyurea"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Polycythemia vera","slug":"polycythemia-vera"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["hematology"]},"trial":{"acronym":"PROUD-PV","aliases":["PROUD-PV","Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera"],"brief_title":"Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","collaborators":["PharmaEssentia (Co-Sponsor for USA)"],"conditions":["Polycythemia Vera"],"enrollment":{"count":257,"type":"ACTUAL"},"excluded_lookalike_trials":{"reason":"No owner-reviewed lookalike exclusion list.","status":"not_set"},"interventions":[{"name":"Peg-P-IFN-alpha-2b (AOP2014)","synonyms":["AOP2014","P1101"],"type":"DRUG"},{"name":"Hydroxyurea","synonyms":["HU","Hydroxycarbamide","brand name Litalir (or other)"],"type":"DRUG"}],"nct_id":"NCT01949805","official_title":"A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera","overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2016-07","type":"ACTUAL"},"primary_endpoints":[{"description":"Disease response rate is defined as hematocrit \\<45% without phlebotomy (at least 3 months since last phlebotomy), platelets \\<400 G/L, leukocytes \\<10 G/L , and normal spleen size","measure":"Disease response rate","timeFrame":"Month 12"}],"registry_last_updated":"2016-11-28","registry_url":"https://clinicaltrials.gov/study/NCT01949805","short_name":"PROUD-PV","short_name_basis":"registry_acronym","sponsor":"AOP Orphan Pharmaceuticals AG","start_date":{"date":"2013-09"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"PROUD-PV","type":"sponsor_study_id"},{"id":"2012-005259-18","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}